Sreekanth Reddy, MD
Medical Oncology · Vidalia, GANPI 1437199965
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.4%. Reporting peaked in 2019 at $33,307 and has fallen 51.5% since, to $16,167 in 2025. Among medical oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 819 payments — averaging $141.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Seagen Inc.$16K
- Astellas Pharma US Inc$13K
- Bristol Myers Squibb$11K
- Sanofi$9K
- Pfizer$8K
- plus $40K from 54 others
Across 44 payments — averaging $3296.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$58K
- Genentech, Inc.$31K
- F. Hoffmann-la Roche AG$26K
- E.r. Squibb & Sons, L.L.C.$21K
- Merck$7K
- AstraZeneca$1K
What the payments were for
- Consulting fees$31,56727%
- Speaking & faculty fees$58,98251%
- Travel & lodging$6,0645%
- Food & beverage$18,54816%
- Education$8371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,998 in reported general payments places this provider in the 95th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 97 | $1,544,628 |
| ImbruvicaIbrutinib | 61 | $970,068 |
| XtandiEnzalutamide | 63 | $812,842 |
| IbrancePalbociclib | 35 | $519,650 |
| Lenalidomide | 30 | $381,720 |
| PomalystPomalidomide | 13 | $292,240 |
| NubeqaDarolutamide | 18 | $239,829 |
| AlecensaAlectinib Hcl | 12 | $218,017 |
| BosulifBosutinib | 11 | $216,323 |
| Lupron DepotLeuprolide Acetate | 34 | $212,064 |
| EliquisApixaban | 137 | $87,390 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $68,159 |
| Azacitidine | 12 | $31,615 |
| XareltoRivaroxaban | 26 | $26,424 |
| OxycontinOxycodone Hcl | 13 | $12,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $10,732 | $1,544,62897 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $135 | $970,06861 claims |
| PfizerIbrance, Bosulif, Eliquis | $7,663 | $823,364183 claims |
| Astellas Pharma US IncXtandi | $12,560 | $812,84263 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,730 | $292,24013 claims |
| BayerNubeqa | $734 | $239,82918 claims |
| Genentech USA, Inc.Alecensa | $1,979 | $218,01712 claims |
| AbbVieLupron Depot | $2,486 | $212,06434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $383 | $68,15916 claims |
| Johnson & JohnsonXarelto | $591 | $26,42426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Vidalia
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Bradley SumrallMacon$36K
- Erin DunbarAtlanta$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.